Summary: Study finds amyloid-beta plaques may not be the cause of memory loss associated with Alzheimer’s disease, but instead a consequence of the disease. Regardless of the levels of amyloid plaques, researchers found individuals with high levels of amyloid peptide were cognitively normal. Higher levels of soluble amyloid beta peptide were also linked to people having a larger hippocampus.
Source: University of Cincinnati.
Experts estimate more than 6 million Americans are living with Alzheimer’s dementia. But a recent study, led by the University of Cincinnati, sheds new light on the disease and a highly debated new drug therapy.
In this video, Drs Irina and Mike Conboy talk about the procedure of Neutral Blood Exchange. How it is done and how much blood of the blood is exchanged.
Our guests today are Drs. Irina and Michael Conboy of the Department of Bioengineering at the University of California Berkeley. their discovery of the rejuvenating effects of young blood through parabiosis in a seminal paper published in Nature in 2005 paved the way for a thriving field of rejuvenation biology. The Conboy lab currently focuses on broad rejuvenation of tissue maintenance and repair, stem cell niche engineering, elucidating the mechanisms underlying muscle stem cell aging, directed organogenesis, and making CRISPR a therapeutic reality.
Papers mentioned in this video. Plasma dilution improves cognition and attenuates neuroinflammation in old mice. https://pubmed.ncbi.nlm.nih.gov/33191466/ Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin. https://pubmed.ncbi.nlm.nih.gov/32474458/ Rejuvenation of aged progenitor cells by exposure to a young systemic environment. https://pubmed.ncbi.nlm.nih.gov/15716955/
************************************************************ Health claims Disclosure: Information provided on this video is not a substitute for direct, individual medical treatment or advice. Please consult with your doctor first. Products or services mentioned in this video are not a recommendation.
Audio Copyright Disclaimer: Please note that we have full authorization to the music that we used in our videos as they were created using the service WeVideo which provides the rights to the music. The rights are detailed in the terms of use that can be reviewed here https://www.wevideo.com/terms-of-use and any following inquiries should be addressed to [email protected]. ***************************************************************** If you would like to support our channel, we’d love a coffee…thank you! https://www.buymeacoffee.com/mhealthspan.
Scientists develop the first CRISPR-Cas9-based gene drive in plants which may breed crops better able to withstand drought and disease.
Scientists have discovered a unique form of cell messaging occurring in the human brain that’s not been seen before. Excitingly, the discovery hints that our brains might be even more powerful units of computation than we realized.
Early last year, researchers from institutes in Germany and Greece reported a mechanism in the brain’s outer cortical cells that produces a novel ‘graded’ signal all on its own, one that could provide individual neurons with another way to carry out their logical functions.
By measuring the electrical activity in sections of tissue removed during surgery on epileptic patients and analysing their structure using fluorescent microscopy, the neurologists found individual cells in the cortex used not just the usual sodium ions to ‘fire’, but calcium as well.
Sanofi will apply Google’s artificial intelligence (AI) and cloud computing capabilities toward developing new drugs, through a collaboration whose value was not disclosed.
The companies said they have agreed to create a virtual Innovation Lab to “radically” transform how future medicines and health services are developed and delivered.
Sanofi has articulated three goals for the collaboration with Google: better understand patients and diseases, increase Sanofi’s operational efficiency, and improve the experience of Sanofi patients and customers.
For the first time, CRISPR-Cas9-based gene drive technology has been developed in plants. Enabling the inheritance of both copies of a target gene from a single parent could greatly reduce the generations needed for plant breeding. Establishing this genome editing technology in plants may allow for breeding resilient crops that are better able to withstand drought and disease.
#GenomeEditing #AgBio #CRISPR #Cas9
Gene drives have been established in insects, including fruit flies and mosquitoes, and mammals such as mice. Now, for the first time, the CRISPR-Cas9-based technology that disrupts Mendelian inheritance and allows for selective acquisition of target genes has been developed in plants. Establishing this genome editing technology in plants may allow for breeding resilient crops that are better able to withstand drought and disease.
“This work defies the genetic constraints of sexual reproduction that an offspring inherits 50% of their genetic materials from each parent,” said Yunde Zhao, PhD, professor of cell and developmental biology at the University of California, San Diego (UCSD). “This work enables inheritance of both copies of the desired genes from only a single parent. The findings can greatly reduce the generations needed for plant breeding.”
Scientists have revealed a fascinating new design for an incredibly tiny, inflatable spinal cord implant, suited for treating severe chronic back pain that doesn’t respond to medication.
The inflatable electronic device is part of a spinal cord stimulator (SCS) setup, a type of well-established therapy that delivers mild electric currents to a person’s spinal cord via implanted electrodes. That current is sent by a small, implanted pulse generator device, and the whole thing reduces pain because the electrical pulses help to mask pain signals traveling to the brain via the spinal cord.
If that all sounds rather invasive, that’s because it is. But this new device, designed by a team led by scientists from the University of Cambridge in the UK, could help to change that — with less invasive surgery requirements.
Changes in epigenetic age acceleration (EAA) were significant over time, with the biggest increase — 4.9 years — seen immediately after the completion of radiotherapy (PChanges in epigenetic age acceleration (EAA) were significant over time, with the biggest increase — 4.9 years — seen immediately after the completion of radiotherapy (P0.001), reported Canhua Xiao, RN, PhD, of Emory University School of Nursing in Atlanta, and colleagues.
The study also demonstrated that EAA was associated with greater inflammation and fatigue, even up to a year after treatment, they noted in Cancer.
While chronological age is a strong risk factor for chronic health problems, Xiao and colleagues said that it often differs from epigenetic age and may be a limited predictor of age-associated disorders. On the other hand, they noted that epigenetic clocks, based on blood DNA methylation measures, have become reliable aging biomarkers.
In patients with mild cognitive impairment, taking lipophilic statins more than doubles their risk of developing dementia compared to those who do not take statins. According to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting, positron emission tomography (PET) scans of lipophilic statin users revealed a highly significant decline in metabolism in the area of the brain that is first impacted by Alzheimer’s disease.
Statins are medications used to lower cholesterol and reduce the risk of heart attack or stroke. They are the most commonly used drugs in the developed world, and nearly 50 percent of Americans over age 75 use a statin. Different types of statins are available based on a patient’s health needs, including hydrophilic statins that focus on the liver and lipophilic statins that are distributed to tissues throughout the body.
Lipophilic statins include simvastatin, fluvastatin, pitavastatin, lovastatin and atorvastatin. Hydrophilic statins include rosuvastatin and pravastatin.
Researchers at McMaster University have developed a promising new cancer immunotherapy that uses cancer-killing cells genetically engineered outside the body to find and destroy malignant tumors.
The modified “natural killer” cells can differentiate between cancer cells and healthy cells that are often intermingled in and around tumors, destroying only the targeted cells.
The natural killer cells’ ability to distinguish the target cells, even from healthy cells that bear similar markers, brings new promise to this branch of immunotherapy, say members of the research team behind a paper published in the current issue of the journal iScience, newly posted on the PubMed database.
